Isomorphic Labs Chief Executive Officer Demis Hassabis stated that the $5 billion in new capital will accelerate the company's platform scale toward designing hundreds of drugs annually and moving into clinical trials

Activity

Activity (0)
Loading comments...
Opening sign-in…